Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 versus CLINIMIX E 5 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 versus CLINIMIX E 5 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN 3.5% vs CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.
CLINIMIX E 5/10 provides essential amino acids, electrolytes, and dextrose for parenteral nutrition, supporting protein synthesis and energy metabolism. Dextrose supplies glucose for cellular energy, while amino acids serve as substrates for protein synthesis. Electrolytes maintain acid-base balance and osmotic regulation.
Intravenous administration of 500 mL to 1000 mL per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 mL/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.
Intravenous infusion. Dosage is individualized based on patient's metabolic requirements, clinical condition, and laboratory parameters. Typical adult dose: 1.5-2 g amino acids/kg/day and 10-15 g dextrose/kg/day (max 5 mg/kg/min dextrose). Rate: Infuse via central line at ≤ 3 mL/kg/hr initially, titrate up to 100-125 mL/hr. Do not exceed 125 mL/hr.
None Documented
None Documented
The plasma half-life of individual amino acids varies; for total amino acid mixture, the terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic and renal function, reflecting rapid uptake into tissues and metabolism. This half-life is clinically relevant for continuous infusion scheduling.
Amino acids: variable, ~1-2 hours for most, reflecting rapid metabolism and utilization. Dextrose: not applicable as endogenous molecule; infusion half-life ~15-30 minutes due to insulin-mediated clearance. Clinical context: renal impairment prolongs amino acid elimination.
Amino acids are primarily eliminated via hepatic metabolism (deamination, transamination) and renal excretion. The renal excretion accounts for approximately 5-10% of the administered dose as unchanged amino acids; the majority is metabolized, and nitrogen is excreted as urea (80-90% of nitrogen) via urine, with minor fecal losses (<5%).
Amino acids and electrolytes are primarily excreted renally. Dextrose is metabolized to CO2 and water, exhaled via lungs. Unmetabolized dextrose excreted renally if threshold exceeded. Less than 5% biliary/fecal.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution